Clinical Trial

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

Name: Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) — clinical trial record (NCT07499362)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT

Protocol Amendment History 1 change

critical Recruitment opened 2026-04-17

Trial Details

NCT Number	NCT07499362
Lead Sponsor	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Collaborators: Merck KGaA, Darmstadt, Germany
Conditions	Tenosynovial Giant Cell Tumor
Enrollment	20 participants
Start Date	2026-03-26
Primary Completion	2029-11-22 (estimated)
Study Completion	2029-11-22 (estimated)
Updated on ClinicalTrials.gov	2026-08-10